Which has preferable valuation and earnings, EHC or MEDP?

Encompass Health has higher revenue and earnings than Medpace. Encompass Health is trading at a lower price-to-earnings ratio than Medpace, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Encompass Health $5.94B 2.05 $566.20M $6.14 20.13 Medpace $2.53B 6.86 $451.12M $17.06 36.47

Does the media prefer EHC or MEDP?

In the previous week, Medpace had 15 more articles in the media than Encompass Health. MarketBeat recorded 20 mentions for Medpace and 5 mentions for Encompass Health. Medpace's average media sentiment score of 0.57 beat Encompass Health's score of 0.35 indicating that Medpace is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Encompass Health 0 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Medpace 9 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation & earnings, ELV or MEDP?

Elevance Health has higher revenue and earnings than Medpace. Elevance Health is trading at a lower price-to-earnings ratio than Medpace, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Elevance Health $199.13B 0.43 $5.66B $22.50 17.44 Medpace $2.53B 6.86 $451.12M $17.06 36.47

Is ELV or MEDP more profitable?

Medpace has a net margin of 17.67% compared to Elevance Health's net margin of 2.47%. Medpace's return on equity of 110.15% beat Elevance Health's return on equity. Company Net Margins Return on Equity Return on Assets Elevance Health 2.47% 14.64% 5.22% Medpace 17.67% 110.15% 24.84%

Does the media favor ELV or MEDP?

In the previous week, Medpace had 18 more articles in the media than Elevance Health. MarketBeat recorded 20 mentions for Medpace and 2 mentions for Elevance Health. Elevance Health's average media sentiment score of 1.34 beat Medpace's score of 0.57 indicating that Elevance Health is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Elevance Health 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Medpace 9 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation and earnings, HIMS or MEDP?

Medpace has higher revenue and earnings than Hims & Hers Health. Hims & Hers Health is trading at a lower price-to-earnings ratio than Medpace, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Hims & Hers Health $2.35B 2.85 $128.37M -$0.63 N/A Medpace $2.53B 6.86 $451.12M $17.06 36.47

Does the media prefer HIMS or MEDP?

In the previous week, Hims & Hers Health had 22 more articles in the media than Medpace. MarketBeat recorded 42 mentions for Hims & Hers Health and 20 mentions for Medpace. Medpace's average media sentiment score of 0.57 beat Hims & Hers Health's score of 0.07 indicating that Medpace is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Hims & Hers Health 3 Very Positive mention(s) 5 Positive mention(s) 31 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Medpace 9 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation & earnings, IQV or MEDP?

IQVIA has higher revenue and earnings than Medpace. IQVIA is trading at a lower price-to-earnings ratio than Medpace, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio IQVIA $16.31B 2.71 $1.36B $8.06 33.36 Medpace $2.53B 6.86 $451.12M $17.06 36.47

Is IQV or MEDP more profitable?

Medpace has a net margin of 17.67% compared to IQVIA's net margin of 8.10%. Medpace's return on equity of 110.15% beat IQVIA's return on equity. Company Net Margins Return on Equity Return on Assets IQVIA 8.10% 30.25% 6.54% Medpace 17.67% 110.15% 24.84%

Does the media prefer IQV or MEDP?

In the previous week, Medpace had 12 more articles in the media than IQVIA. MarketBeat recorded 20 mentions for Medpace and 8 mentions for IQVIA. Medpace's average media sentiment score of 0.57 beat IQVIA's score of 0.43 indicating that Medpace is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment IQVIA 4 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Medpace 9 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor MEDP or A?

In the previous week, Medpace had 3 more articles in the media than Agilent Technologies. MarketBeat recorded 20 mentions for Medpace and 17 mentions for Agilent Technologies. Agilent Technologies' average media sentiment score of 0.58 beat Medpace's score of 0.57 indicating that Agilent Technologies is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Medpace 9 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Agilent Technologies 7 Very Positive mention(s) 2 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Medpace (MEDP) Competitors

$622.11 +6.17 (+1.00%)

Closing price 04:00 PM Eastern

Extended Trading

$621.96 -0.14 (-0.02%)

As of 04:37 PM Eastern

Compare

MEDP vs. EHC, ELV, HIMS, IQV, and A

Should you buy Medpace stock or one of its competitors? Medpace's main competitors and comparable companies include Encompass Health (EHC), Elevance Health (ELV), Hims & Hers Health (HIMS), IQVIA (IQV), and Agilent Technologies (A). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare" sector.

How does Medpace compare to Encompass Health?

Encompass Health (NYSE:EHC) and Medpace (NASDAQ:MEDP) are both large-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, media sentiment, institutional ownership, risk, earnings, profitability, analyst recommendations and valuation.

Encompass Health presently has a consensus price target of $148.50, indicating a potential upside of 20.14%. Medpace has a consensus price target of $595.20, indicating a potential downside of 4.33%. Given Encompass Health's stronger consensus rating and higher possible upside, research analysts plainly believe Encompass Health is more favorable than Medpace.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Encompass Health	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	3.00
Medpace	0 Sell rating(s)	9 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.25

In the previous week, Medpace had 15 more articles in the media than Encompass Health. MarketBeat recorded 20 mentions for Medpace and 5 mentions for Encompass Health. Medpace's average media sentiment score of 0.57 beat Encompass Health's score of 0.35 indicating that Medpace is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Encompass Health	0 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Medpace	9 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Medpace has a net margin of 17.67% compared to Encompass Health's net margin of 10.01%. Medpace's return on equity of 110.15% beat Encompass Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Encompass Health	10.01%	18.08%	8.22%
Medpace	17.67%	110.15%	24.84%

97.3% of Encompass Health shares are owned by institutional investors. Comparatively, 78.0% of Medpace shares are owned by institutional investors. 1.8% of Encompass Health shares are owned by insiders. Comparatively, 20.5% of Medpace shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Encompass Health has higher revenue and earnings than Medpace. Encompass Health is trading at a lower price-to-earnings ratio than Medpace, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Encompass Health	$5.94B	2.05	$566.20M	$6.14	20.13
Medpace	$2.53B	6.86	$451.12M	$17.06	36.47

Encompass Health has a beta of 0.75, suggesting that its share price is 25% less volatile than the broader market. Comparatively, Medpace has a beta of 1.15, suggesting that its share price is 15% more volatile than the broader market.

Summary

Medpace beats Encompass Health on 10 of the 17 factors compared between the two stocks.

How does Medpace compare to Elevance Health?

Elevance Health (NYSE:ELV) and Medpace (NASDAQ:MEDP) are both large-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, risk, dividends, valuation, institutional ownership, profitability, earnings and analyst recommendations.

Elevance Health has a beta of 0.69, suggesting that its stock price is 31% less volatile than the broader market. Comparatively, Medpace has a beta of 1.15, suggesting that its stock price is 15% more volatile than the broader market.

Elevance Health presently has a consensus price target of $440.90, indicating a potential upside of 12.35%. Medpace has a consensus price target of $595.20, indicating a potential downside of 4.33%. Given Elevance Health's stronger consensus rating and higher probable upside, equities analysts plainly believe Elevance Health is more favorable than Medpace.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Elevance Health	0 Sell rating(s)	8 Hold rating(s)	15 Buy rating(s)	0 Strong Buy rating(s)	2.65
Medpace	0 Sell rating(s)	9 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.25

In the previous week, Medpace had 18 more articles in the media than Elevance Health. MarketBeat recorded 20 mentions for Medpace and 2 mentions for Elevance Health. Elevance Health's average media sentiment score of 1.34 beat Medpace's score of 0.57 indicating that Elevance Health is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Elevance Health	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Medpace	9 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Elevance Health has higher revenue and earnings than Medpace. Elevance Health is trading at a lower price-to-earnings ratio than Medpace, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Elevance Health	$199.13B	0.43	$5.66B	$22.50	17.44
Medpace	$2.53B	6.86	$451.12M	$17.06	36.47

89.2% of Elevance Health shares are owned by institutional investors. Comparatively, 78.0% of Medpace shares are owned by institutional investors. 0.3% of Elevance Health shares are owned by company insiders. Comparatively, 20.5% of Medpace shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Medpace has a net margin of 17.67% compared to Elevance Health's net margin of 2.47%. Medpace's return on equity of 110.15% beat Elevance Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Elevance Health	2.47%	14.64%	5.22%
Medpace	17.67%	110.15%	24.84%

Summary

Elevance Health and Medpace tied by winning 8 of the 16 factors compared between the two stocks.

How does Medpace compare to Hims & Hers Health?

Hims & Hers Health (NYSE:HIMS) and Medpace (NASDAQ:MEDP) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, risk, media sentiment, institutional ownership, earnings and profitability.

Hims & Hers Health currently has a consensus target price of $32.43, suggesting a potential upside of 13.20%. Medpace has a consensus target price of $595.20, suggesting a potential downside of 4.33%. Given Hims & Hers Health's higher possible upside, equities analysts plainly believe Hims & Hers Health is more favorable than Medpace.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hims & Hers Health	1 Sell rating(s)	12 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.13
Medpace	0 Sell rating(s)	9 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.25

In the previous week, Hims & Hers Health had 22 more articles in the media than Medpace. MarketBeat recorded 42 mentions for Hims & Hers Health and 20 mentions for Medpace. Medpace's average media sentiment score of 0.57 beat Hims & Hers Health's score of 0.07 indicating that Medpace is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Hims & Hers Health	3 Very Positive mention(s)	5 Positive mention(s)	31 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Medpace	9 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Hims & Hers Health has a beta of 2.42, indicating that its stock price is 142% more volatile than the broader market. Comparatively, Medpace has a beta of 1.15, indicating that its stock price is 15% more volatile than the broader market.

63.5% of Hims & Hers Health shares are held by institutional investors. Comparatively, 78.0% of Medpace shares are held by institutional investors. 11.8% of Hims & Hers Health shares are held by insiders. Comparatively, 20.5% of Medpace shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Medpace has a net margin of 17.67% compared to Hims & Hers Health's net margin of -5.51%. Medpace's return on equity of 110.15% beat Hims & Hers Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hims & Hers Health	-5.51%	-6.51%	-1.20%
Medpace	17.67%	110.15%	24.84%

Medpace has higher revenue and earnings than Hims & Hers Health. Hims & Hers Health is trading at a lower price-to-earnings ratio than Medpace, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hims & Hers Health	$2.35B	2.85	$128.37M	-$0.63	N/A
Medpace	$2.53B	6.86	$451.12M	$17.06	36.47

Summary

Medpace beats Hims & Hers Health on 12 of the 15 factors compared between the two stocks.

How does Medpace compare to IQVIA?

IQVIA (NYSE:IQV) and Medpace (NASDAQ:MEDP) are both large-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, analyst recommendations, dividends, media sentiment, institutional ownership, earnings, valuation and profitability.

In the previous week, Medpace had 12 more articles in the media than IQVIA. MarketBeat recorded 20 mentions for Medpace and 8 mentions for IQVIA. Medpace's average media sentiment score of 0.57 beat IQVIA's score of 0.43 indicating that Medpace is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
IQVIA	4 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Medpace	9 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

89.6% of IQVIA shares are held by institutional investors. Comparatively, 78.0% of Medpace shares are held by institutional investors. 1.7% of IQVIA shares are held by company insiders. Comparatively, 20.5% of Medpace shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

IQVIA has higher revenue and earnings than Medpace. IQVIA is trading at a lower price-to-earnings ratio than Medpace, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IQVIA	$16.31B	2.71	$1.36B	$8.06	33.36
Medpace	$2.53B	6.86	$451.12M	$17.06	36.47

IQVIA has a beta of 1.18, indicating that its share price is 18% more volatile than the broader market. Comparatively, Medpace has a beta of 1.15, indicating that its share price is 15% more volatile than the broader market.

IQVIA currently has a consensus target price of $257.75, suggesting a potential downside of 4.14%. Medpace has a consensus target price of $595.20, suggesting a potential downside of 4.33%. Given IQVIA's stronger consensus rating and higher probable upside, equities research analysts plainly believe IQVIA is more favorable than Medpace.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IQVIA	0 Sell rating(s)	3 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.88
Medpace	0 Sell rating(s)	9 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.25

Medpace has a net margin of 17.67% compared to IQVIA's net margin of 8.10%. Medpace's return on equity of 110.15% beat IQVIA's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IQVIA	8.10%	30.25%	6.54%
Medpace	17.67%	110.15%	24.84%

Summary

Medpace beats IQVIA on 9 of the 17 factors compared between the two stocks.

How does Medpace compare to Agilent Technologies?

Medpace (NASDAQ:MEDP) and Agilent Technologies (NYSE:A) are both large-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, media sentiment, profitability, dividends, analyst recommendations and valuation.

Agilent Technologies has a net margin of 19.53% compared to Medpace's net margin of 17.67%. Medpace's return on equity of 110.15% beat Agilent Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Medpace	17.67%	110.15%	24.84%
Agilent Technologies	19.53%	24.45%	13.09%

Agilent Technologies has higher revenue and earnings than Medpace. Agilent Technologies is trading at a lower price-to-earnings ratio than Medpace, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Medpace	$2.53B	6.86	$451.12M	$17.06	36.47
Agilent Technologies	$6.95B	7.11	$1.30B	$5.08	34.47

Medpace has a beta of 1.15, meaning that its share price is 15% more volatile than the broader market. Comparatively, Agilent Technologies has a beta of 1.24, meaning that its share price is 24% more volatile than the broader market.

Medpace presently has a consensus target price of $595.20, indicating a potential downside of 4.33%. Agilent Technologies has a consensus target price of $170.33, indicating a potential downside of 2.72%. Given Agilent Technologies' stronger consensus rating and higher possible upside, analysts plainly believe Agilent Technologies is more favorable than Medpace.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Medpace	0 Sell rating(s)	9 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.25
Agilent Technologies	0 Sell rating(s)	5 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.80

In the previous week, Medpace had 3 more articles in the media than Agilent Technologies. MarketBeat recorded 20 mentions for Medpace and 17 mentions for Agilent Technologies. Agilent Technologies' average media sentiment score of 0.58 beat Medpace's score of 0.57 indicating that Agilent Technologies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Medpace	9 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Agilent Technologies	7 Very Positive mention(s)	2 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

78.0% of Medpace shares are owned by institutional investors. 20.5% of Medpace shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Agilent Technologies beats Medpace on 10 of the 17 factors compared between the two stocks.

Get Medpace News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MEDP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MEDP vs. The Competition

Export

Metric	Medpace	Life Sciences Tools & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$17.36B	$10.99B	$7.26B	$13.03B
Dividend Yield	N/A	1.45%	2.52%	14.03%
P/E Ratio	36.47	75.39	274.98	25.67
Price / Sales	6.86	109.08	606.85	80.71
Price / Cash	36.38	27.55	28.02	35.00
Price / Book	38.17	6.35	10.50	6.43
Net Income	$451.12M	$57.48B	$3.50B	$360.21M
7 Day Performance	-1.28%	2.89%	-3.01%	-2.82%
1 Month Performance	3.57%	6.16%	-4.15%	-4.09%
1 Year Performance	24.23%	42.59%	13.25%	3.83%

Medpace Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MEDP Medpace	2.3455 of 5 stars	$622.11 +1.0%	$595.20 -4.3%	+24.0%	$17.36B	$2.53B	36.47	6,500
EHC Encompass Health	4.7596 of 5 stars	$121.84 +0.1%	$148.20 +21.6%	-2.2%	$12.01B	$5.94B	19.84	42,000	Analyst Upgrade
ELV Elevance Health	4.4806 of 5 stars	$409.43 -0.4%	$440.90 +7.7%	+23.9%	$89.12B	$199.13B	18.20	97,100	Positive News
HIMS Hims & Hers Health	2.2239 of 5 stars	$29.43 +5.1%	$32.43 +10.2%	-50.8%	$6.53B	$2.35B	N/A	2,442	Trending News Gap Up
IQV IQVIA	2.8292 of 5 stars	$270.69 +1.6%	$248.00 -8.4%	+51.0%	$43.85B	$16.31B	33.58	93,000	Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MEDP) was last updated on 9/29/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Medpace (MEDP) Competitors

MEDP vs. EHC, ELV, HIMS, IQV, and A

How does Medpace compare to Encompass Health?

Summary

How does Medpace compare to Elevance Health?

Summary

How does Medpace compare to Hims & Hers Health?

Summary

How does Medpace compare to IQVIA?

Summary

How does Medpace compare to Agilent Technologies?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MEDP vs. The Competition

Medpace Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Medpace (MEDP) Competitors

MEDP vs. EHC, ELV, HIMS, IQV, and A

How does Medpace compare to Encompass Health?

Do analysts recommend EHC or MEDP?

Does the media prefer EHC or MEDP?

Is EHC or MEDP more profitable?

Do institutionals and insiders believe in EHC or MEDP?

Which has preferable valuation and earnings, EHC or MEDP?

Which has more volatility and risk, EHC or MEDP?

Summary

How does Medpace compare to Elevance Health?

Which has more risk and volatility, ELV or MEDP?

Do analysts recommend ELV or MEDP?

Does the media favor ELV or MEDP?

Which has higher valuation & earnings, ELV or MEDP?

Do insiders & institutionals believe in ELV or MEDP?

Is ELV or MEDP more profitable?

Summary

How does Medpace compare to Hims & Hers Health?

Do analysts prefer HIMS or MEDP?

Does the media prefer HIMS or MEDP?

Which has more volatility & risk, HIMS or MEDP?

Do insiders & institutionals hold more shares of HIMS or MEDP?

Is HIMS or MEDP more profitable?

Which has higher valuation and earnings, HIMS or MEDP?

Summary

How does Medpace compare to IQVIA?

Does the media prefer IQV or MEDP?

Do institutionals & insiders believe in IQV or MEDP?

Which has stronger valuation & earnings, IQV or MEDP?

Which has more risk & volatility, IQV or MEDP?

Do analysts prefer IQV or MEDP?

Is IQV or MEDP more profitable?

Summary

How does Medpace compare to Agilent Technologies?

Is MEDP or A more profitable?

Which has higher valuation and earnings, MEDP or A?

Which has more risk and volatility, MEDP or A?

Do analysts prefer MEDP or A?

Does the media favor MEDP or A?

Do insiders & institutionals have more ownership in MEDP or A?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MEDP vs. The Competition

Medpace Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools